Hydroxyurea Reaffirmed as First-Line Choice in Sickle Cell Density Care
Akshat Jain, Medical Director at Loma Linda University Children’s Health, shared a recent article by Susan Creary, Associate Professor of Pediatrics and pediatric hematologist in the division of Hematology/Oncology/BMT, on X:
“As the sickle cell disease community struggles with available treatment options that are accessible and affordable by all, new data in this paper encouraging safety of Hydroxyurea reaffirms it the first line choice still for our patients in the global SCD care space.
Summary – Follicle density is a good surrogate marker for fertility / chances for successful childbearing. HU may have no impact on the follicle density of young women with SCD.”
Title: Hydroxyurea and follicle density in sickle cell
Authors: Susan CrearyChelsea Kebodeaux and Leena Nahata
Dr. Akshat Jain, M.D., M.P.H., is a Medical Director at Loma Linda University Children’s Health, overseeing the Pediatric and Young Adult Hemostasis/Thrombosis and Sickle Cell Disease Program. He serves as a Clinical Faculty member in Pediatric Hematology Oncology at Loma Linda University Medical Center and is on the Clinical Science Faculty Advisory Council. Additionally, he is an Assistant Professor at the Loma Linda University School of Public Health and a Review Board Member for Hemostasis with the American Academy of Pediatrics.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023